Sun, Aug 31, 2014, 5:29 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Savient Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • kg2931 kg2931 Mar 21, 1999 9:47 PM Flag

    Deleted Message

    Who has BTGC's investor relations web site? The
    Oxandrin page gives nothing. The following is apparently
    under construction:
    http://www.btgc.com/

    It's
    time all us small time faithfull long term holders of
    BTGC stock inundate BTGC Investor Relations with our
    questions/concerns/protests NOWWWWWWWWWWWWWWWWWWWWWWWWWWW.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't think you can reach them via email ...
      they don't post any email addresses in their quarterly
      reports or in press releases. I'd suggest you do what I
      do and pick up the phone and call them ...
      732-632-8800 (NJ Headquarters) or 212-947-9800 (NY Office). I
      spoke to them for 1/2 hour Friday and suggest you do
      the same. Ask them tough questions. While I'm
      disappointed in the stock performance I'm buying more at these
      levels and will trade it shorter term to make a few
      bucks. The recent Merrill Lynch report indicated that
      Oxandrol scrips were up 26% in Jan/Feb 1999 vs. the same
      period in 1998, so hopefully the weak Oxandrol numbers
      in Q4 were due to inventory problems.

      • 1 Reply to dhohhi
      • of 1998 were lower due to a decision to decrease
        Oxandrin inventory levels at Olsten Corporation resulting
        in lower new orders despite growing number of new
        scrips. Inventory has now been reduced and increased
        sales will be reported in the first quarter, as you
        indicated. Oxandrin is continuing to increase market share.
        Announcement of partner to jointly market Oxandrin in the U.S.
        for wound care (700k patients per year market) should
        be forthcoming later in March or April. In the
        Wedbush recommendation in Barron's mentions, a new market
        for Oxandrin for wound care mid-1999. It also
        projected a P/E of 13 for the year 2000.

        Other
        reasons BTG will climb:

        - Biotropin (HGH) now
        being sold by Sumitomo (50% market share) in Japan as
        of January 1. Sumitomo 's previous partner Upjohn,
        now going it alone in Japan, will compete against
        Sumitomo resulting in market share loss of about half. BTG
        through its original distributor JCR had 1998 sales in
        Japan of $10 million ($17 million worldwide) and 8%
        market share. With 33% (25%+8%) market share, sales in
        Japan should jump from $10 million to $41 million.
        Order in 1999 are strong and growing.

        -
        Purchasing of late stage drugs\companies is in process; to
        occur in the mid-1999 timeframe.

        - Biolon being
        marketed by two distributors in U.S. market.

        -
        BTG hepatitis-B vaccine (Bio-Hep-B)new drug
        application should be approved by the Isreali government by
        June. Isreal has only approved one other drug that was
        not approved by the FDA? What company sells that
        drug? Answer - BTG received approval for Biotropin
        without FDA approval.

        - Drugs under development
        for bigger markets.

        - BTG to meet with FDA in
        April for Androtab phase III trial.

        - BTG under
        phase II will evaluate data on the 295 infants given
        OxSoDrol.

 
SVNTQ
0.00190.0000(0.00%)May 30 3:56 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.